{"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"0.02642","statisticalMethod":"Wilcoxon (Mann-Whitney)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.42","upperLimit":"1.27","value":"0.943"}]}],"title":"Treated with Vorinostat"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.19","upperLimit":"1.01","value":"0.679"}]}],"title":"Not Treated with Vorinostat"}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"Median Ac-H3 levels ( depicted as a ratio of ac-H2 optical density (OD) and beta actin OD) were compared in patients treated with Vorinostat to patients not treated with Vorinostat. Optical Density is a dimensionless unit.","dispersionType":"Full Range","groups":[{"description":"Patients receive vorinostat PO BID on days -10 to 100. Beginning on day -3, patients receive tacrolimus IV continuously or PO BID (or cyclosporine IV continuously or PO in patients unable to tolerate tacrolimus) with taper on days 100-180. Patients also receive methotrexate IV QD on days 1, 3, 6, and 11.","id":"OG000","title":"Supportive Care (Vorinostat, Tacrolimus, Methotrexate)"}],"paramType":"MEDIAN","populationDescription":"This trial consisted of an initial pilot phase, funded by the NCI, that enrolled 12 patients (NCT01789255). The trial was extended to enroll an additional 25 patients. The results presented here include information for all 37 patients. The analysis population description for all 37 patients can be found under NCT01790568.","reportingStatus":"POSTED","timeFrame":"Up to day 100","title":"Median Ac-H3 Levels in Patients Treated With Vorinostat and Patients Not Treated With Vorinostat","type":"SECONDARY","unitOfMeasure":"Ratio"}